title: Importance of psychological well being and disease activity in termination of an initial DMARD therapy.
abstract: OBJECTIVE
  To estimate the frequency of and to identify possible risk factors involved with terminating an initial disease modifying antirheumatic drug (DMARD) therapy. We hypothesized that treatment termination depends not only on side effects and inefficacy but also on the therapeutic setting and the health beliefs of the patient.
  
  
  METHODS
  We observed an inception cohort of 302 patients with early rheumatoid arthritis (< 2 years) and first prescription of DMARD for 3 years. Survival analysis was used to estimate treatment continuation under rheumatological care. The study group comprised 4 rheumatological outpatient clinics and 7 private practices in Berlin.
  
  
  RESULTS
  Of the initial cohort 80% continued the same drug or were in remission after one year, 70% after 2 years. Within the first 2 years, methotrexate therapy was terminated in 15% of the cases and sulfasalazine therapy in 40%, respectively. In both forms of therapy, the discontinuation rate was dependent on initial disease activity. However, the influence of the patient's psychological status at baseline was equally strong. DMARD treatment was terminated earlier and more frequently in patients with poor psychological well being. These findings hold true after controlling for disease activity or severity.
  
  
  CONCLUSIONS
  Patient psychological well being and disease activity at start of initial DMARD therapy are important predictors of early drug discontinuation. By influencing psychological well being (e.g., by patient education programs), continuation of DMARD therapy might be further improved.
authors.affiliation: Epidemiology Unit, German Rheumatism Research Center, Schlosspark Hospital, Berlin.
authors.forename: J
authors.initials: J
authors.lastname: Listing
authors.forename: R
authors.initials: R
authors.lastname: Alten
authors.forename: D
authors.initials: D
authors.lastname: Brauer
authors.forename: U
authors.initials: U
authors.lastname: Eggens
authors.forename: E
authors.initials: E
authors.lastname: Gromnica-Ihle
authors.forename: D
authors.initials: D
authors.lastname: Hagemann
authors.forename: R
authors.initials: R
authors.lastname: Hauer
authors.forename: D
authors.initials: D
authors.lastname: Milleck
authors.forename: U
authors.initials: U
authors.lastname: Reuter
authors.forename: R
authors.initials: R
authors.lastname: Schlittgen
authors.forename: H
authors.initials: H
authors.lastname: Sörensen
authors.forename: A
authors.initials: A
authors.lastname: Zink
mesh_terms: D000328:Adult; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000523:psychology*; D001294:Attitude to Health; D015331:Cohort Studies; D005260:Female; D006304:Health Status; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011336:Probability; D011581:Psychological Tests; D012307:Risk Factors; D012460:Sulfasalazine / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D012460:Sulfasalazine; D008727:Methotrexate